Lung, Lung - Non-Small Cell, Molecular Profiling
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
(See required screening study ALLIANCE A151216)
Eligible for screening study DCP 001
A081105 is reactivated effective July 15, 2020.